Impella辅助治疗急性心肌梗死合并心源性休克
该回顾性研究在372例急性心肌梗死合并心源性休克患者中,将237例使用Impella者与IABP-SHOCK II试验匹配的237例对照比较,发现30天全因死亡率无显著差异(48.5% vs 46.4%,P=0.64),但Impella组严重出血和血管并发症更多。
要点
- Impella与IABP或药物治疗相比,30天全因死亡率无显著降低。
- Impella组严重或危及生命出血(8.5% vs 3.0%)及外周血管并发症(9.8% vs 3.8%)显著增加。
- 仅以IABP治疗患者为对照时,结果不变。
核心结论
- 在急性心肌梗死合并心源性休克患者中,使用Impella装置与匹配的IABP-SHOCK II试验患者相比,30天死亡率无显著降低。
研究设计与样本
- 回顾性研究,收集欧洲三级医院接受Impella治疗的AMI-CS患者数据,按IABP-SHOCK II标准识别372例,最终237例与IABP-SHOCK II试验237例进行匹配。
主要发现
- 匹配后30天全因死亡率:Impella组48.5% vs 对照组46.4%,P=0.64,无显著差异。
- Impella组严重或危及生命出血发生率为8.5% vs 3.0%,P<0.01。
- Impella组外周血管并发症发生率为9.8% vs 3.8%,P=0.01。
- 仅以IABP治疗患者为对照时,结果不变。
临床怎么用
- 对于AMI-CS患者,Impella支持未显示较IABP或药物治疗降低30天死亡率,且出血和血管并发症风险更高。
局限性
- 回顾性分析,非随机对照,需大型随机试验进一步评估Impella对AMI-CS结局的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Percutaneous mechanical circulatory support devices are increasingly used in acute myocardial infarction complicated by cardiogenic shock (AMI-CS), despite limited evidence for their effectiveness. The aim of this study was to evaluate outcomes associated with use of the Impella device compared with intra-aortic balloon pump (IABP) and medical treatment in patients with AMI-CS. METHODS: Data of patients with AMI-CS treated with the Impella device at European tertiary care hospitals were collected retrospectively. All patients underwent early revascularization and received optimal medical treatment. Using IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial inclusion and exclusion criteria, 372 patients were identified and included in this analysis. These patients were matched to 600 patients from the IABP-SHOCK II trial. The following baseline criteria were used as matching parameters: age, sex, mechanical ventilation, ejection fraction, prior cardiopulmonary resuscitation, and lactate. Primary end point was 30-day all-cause mortality. RESULTS: In total, 237 patients treated with an Impella could be matched to 237 patients from the IABP-SHOCK II trial. Baseline parameters were similarly distributed after matching. There was no significant difference in 30-day all-cause mortality (48.5% versus 46.4%, P=0.64). Severe or life-threatening bleeding (8.5% versus 3.0%, P<0.01) and peripheral vascular complications (9.8% versus 3.8%, P=0.01) occurred significantly more often in the Impella group. Limiting the analysis to IABP-treated patients as a control group did not change the results. CONCLUSIONS: In this retrospective analysis of patients with AMI-CS, the use of an Impella device was not associated with lower 30-day mortality compared with matched patients from the IABP-SHOCK II trial treated with an IABP or medical therapy. To further evaluate this, a large randomized trial is warranted to determine the effect of the Impella device on outcome in patients with AMI-CS. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03313687.
引用
- Schrage B, Ibrahim K, Loehn T, et al. Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation. 2019. PMID: 30586755. doi:10.1161/CIRCULATIONAHA.118.036614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。